SCHEMBL4256027

SCHEMBL4256027

COC(=O)Cc1c(C(=O)c2ccccc2-c2ccccc2)sc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACA Q13085 1/20 0.46
▸ PRNP P04156 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ HPGD P15428 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CHRNB2 P17787 2/20 0.41
▸ CHRNA4 P43681 2/20 0.41
▸ CHRNB4 P30926 1/20 0.41
▸ CHRNA3 P32297 1/20 0.41
▸ GAA P10253 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262484 0.87 PRNP (0.46) ACACAPRNPRXFP1LMNAMAPK1
SCHEMBL16504066 0.74 KDM4E (0.50) LMNAMAPK1CNR2HPGDRAB9A
SCHEMBL12925954 0.73 EGFR (0.47) ACACALMNAMAPK1HPGDRAB9A
SCHEMBL5049332 0.70 LMNA (0.65) LMNAMAPK1HPGDGAAKDM4E
SCHEMBL10566048 0.69 ALDH1A1 (0.57) RXFP1LMNAMAPK1HPGDSMN1; SMN2
SCHEMBL8171489 0.69 MAOB (0.48) LMNACNR1CNR2HPGDRAB9A
SCHEMBL29831624 0.68 KDM4E (0.47) LMNAMAPK1HPGDRAB9ANPC1
SCHEMBL20839925 0.67 LMNA (0.65) LMNAMAPK1CNR2HPGDGAA
SCHEMBL1193932 0.67 KDM4E (0.43) ACACALMNAMAPK1CNR2HPGD
SCHEMBL11599859 0.67 MAPT (0.50) PRNPRXFP1LMNAMAPK1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134683-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2009-12-23 — — EP disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS ACACA 227/4885PRNP 1827/4885RXFP1 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback